Magnetic resonance imaging biomarkers in hepatocellular carcinoma: Association with response and circulating biomarkers after sunitinib therapy

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Sahani, Dushyant V ^a   Jiang, Tao ^a,b   Hayano, Koichi ^a   Duda, Dan G ^a   Catalano, Onofrio A ^a,c   Ancukiewicz, Marek ^a   Jain, Rakesh K ^a   Zhu, Andrew X ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c IRCCS SDN   (Italy)

Author keywords

Antiangiogenic treatment; Circulating biomarker; Diffusion weighted imaging; Dynamic contrast enhanced MRI; Hepatocellular carcinoma; Image biomarker

Indexed keywords

INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; SUNITINIB; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN C;

ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD VESSEL PERMEABILITY; CANCER SURVIVAL; CLINICAL ARTICLE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG DOSE REDUCTION; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LONG QT SYNDROME; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR THROMBUS; TUMOR VOLUME; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDOLES; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PYRROLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84879998925     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-51     Document Type: Article

References (43)

1. Cancer statistics, 2010. Jemal A, Siegel R, Xu J, Ward E, CA Cancer J Clin 2010 60 277 300 10.3322/caac.20073 20610543
2. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. Giglia JL, Antonia SJ, Berk LB, Bruno S, Dessureault S, Finkelstein SE, Cancer Control 2010 17 120 129 20404795
3. Systemic therapy for hepatocellular carcinoma. Thomas MB, Cancer J 2008 14 123 127 10.1097/PPO.0b013e31816a6058 18391618
4. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Murukesh N, Dive C, Jayson GC, Br J Cancer 2010 102 8 18 10.1038/sj.bjc.6605483 20010945
5. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Wörns MA, Schuchmann M, Düber C, Otto G, Galle PR, Weinmann A, Oncology 2010 79 85 92 10.1159/000320363 21071995
6. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T, Rashid A, Dancey J, Abbruzzese JL, Cancer 2007 110 1059 1067 10.1002/cncr.22886 17623837 (Pubitemid 47312872)
7. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S, Schwartz JD, J Clin Oncol 2008 26 2992 2998 10.1200/JCO.2007.15.9947 18565886
8. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Zhu AX, Duda DG, Sahani DV, Jain RK, Cancer J 2009 15 263 268 10.1097/PPO.0b013e3181af5e35 19672141
9. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV, Oncologist 2008 13 120 125 10.1634/theoncologist.2007-0174 18305056 (Pubitemid 351342575)
10. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, McCleary NJ, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG, Clin Cancer Res 2013 19 1557 1566 10.1158/1078-0432.CCR-12-3041 23362324
11. HCC and angiogenesis: possible targets and future directions. Zhu AX, Duda DG, Sahani DV, Jain RK, Nat Rev Clin Oncol 2011 8 292 301 10.1038/nrclinonc.2011.30 21386818
12. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK, J Clin Oncol 2009 27 3027 3035 10.1200/JCO.2008.20.9908 19470923
13. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M, Lanzalone S, Lin X, Deprimo S, Harmon C, Ruiz-Garcia A, Lechuga MJ, Cheng AL, Lancet Oncol 2009 10 794 800 10.1016/S1470-2045(09)70171-8 19586800
14. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Marcus CD, Ladam-Marcus V, Cucu C, Bouche O, Lucas L, Hoeffel C, Crit Rev Oncol Hematol 2009 72 217 238 10.1016/j. critrevonc.2008.07.012 18760935
15. EASL panel of experts on HCC: clinical management of hepatocellular carcinoma. Conclusions of the barcelona-2000 EASL conference. European association for the study of the liver. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodés J, J Hepatol 2001 35 421 430 10.1016/S0168-8278(01)00130-1 11592607 (Pubitemid 32844200)
16. Panel of experts in HCC-design clinical trials: design and endpoints of clinical trials in hepatocellular carcinoma. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ, J Natl Cancer Inst 2008 100 698 711 10.1093/jnci/djn134 18477802
17. Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. Jiang T, Zhu AX, Sahani DV, J Hepatol 2013 58 169 177 10.1016/j.jhep.2012.08.022 22944253
18. Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. Zech CJ, Reiser MF, Herrmann KA, Dig Dis 2009 27 114 124 10.1159/000218343 19546549
19. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Jarnagin WR, Schwartz LH, Gultekin DH, Gönen M, Haviland D, Shia J, D'Angelica M, Fong Y, Dematteo R, Tse A, Blumgart LH, Kemeny N, Ann Oncol 2009 20 1589 1595 10.1093/annonc/mdp029 19491285
20. Role of diffusion-weighted imaging in evaluating therapeutic efficacy after transcatheter arterial chemoembolization for hepatocellular carcinoma. Kubota K, Yamanishi T, Itoh S, Murata Y, Miyatake K, Yasunami H, Morio K, Hamada N, Nishioka A, Ogawa Y, Oncol Rep 2010 24 727 732 20664980
21. Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization. Chung JC, Naik NK, Lewandowski RJ, Deng J, Mulcahy MF, Kulik LM, Sato KT, Ryu RK, Salem R, Larson AC, Omary RA, World J Gastroenterol 2010 16 3161 3167 10.3748/wjg.v16.i25.3161 20593501
22. Enhancing and expansile portal vein thrombosis: value in the diagnosis of hepatocellular carcinoma in patients with multiple hepatic lesions. Shah ZK, McKernan MG, Hahn PF, Sahani DV, AJR Am J Roentgenol 2007 188 1320 1323 10.2214/AJR.06.0134 17449777 (Pubitemid 46668515)
23. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Catalano OA, Choy G, Zhu A, Hahn PF, Sahani DV, Radiology 2010 254 154 162 10.1148/radiol.09090304 20032150
24. Estimating the arterial input function using two reference tissues in dynamic contrast-enhanced MRI studies: fundamental concepts and simulations. Yang C, Karczmar GS, Medved M, Stadler WM, Magn Reson Med 2004 52 1110 1117 10.1002/mrm.20243 15508148 (Pubitemid 39453285)
25. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM, J Magn Reson Imaging 1999 10 223 232 10.1002/(SICI)1522-2586(199909)10:3<223::AID- JMRI2>3.0.CO;2-S 10508281 (Pubitemid 29463104)
26. Phase I dose-finding study of pazooanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Yau T, Chen PJ, Chan P, Curtis CM, Murphy PS, Suttle AB, Gauvin J, Hodge JP, Dar MM, Poon RT, Clin Cancer Res 2011 17 6914 6923 10.1158/1078-0432.CCR-11-0793 21831954
27. Dynamic contrst-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. Hsu CY, Shen YC, Yu CW, Hsu C, Hu FC, Hsu CH, Chen BB, Wei SY, Cheng AL, Shih TTF, J Hepatol 2011 55 858 865 10.1016/j.jhep.2011.01.032 21338641
28. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. de Langen AJ, van den Boogaart V, Lubberink M, Backes WH, Marcus JT, van Tinteren H, Pruim J, Brans B, Leffers P, Dingemans AM, Smit EF, Groen HJ, Hoekstra OS, J Nucl Med 2011 52 48 55 10.2967/jnumed.110.078261 21149474
29. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy. Pickles MD, Lowry M, Manton DJ, Gibbs P, Turnbull LW, Breast Cancer Res Treat 2005 91 1 10 10.1007/s10549-004-5819-2 15868426 (Pubitemid 40684933)
30. Predicting control of primary tumor and survival by DCE MRI during early therapy in cervical cancer. Yuh WT, Mayr NA, Jarjoura D, Wu D, Grecula JC, Lo SS, Edwards SM, Magnotta VA, Sammet S, Zhang H, Montebello JF, Fowler J, Knopp MV, Wang JZ, Invest Radiol 2009 44 343 350 10.1097/RLI.0b013e3181a64ce9 19661844
31. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marmé D, Steward WP, J Clin Oncol 2003 21 3955 3964 10.1200/JCO.2003.08.092 14517187 (Pubitemid 46606209)
32. A comparison of ktrans measurements obtained with conventional and first pass pharmacokinetic models in human gliomas. Haroon HA, Buckley DL, Patankar TA, Dow GR, Rutherford SA, Balériaux D, Jackson A, J Magn Reson Imaging 2004 19 527 536 10.1002/jmri.20045 15112301 (Pubitemid 38619914)
33. Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging. Barboriak DP, MacFall JR, Viglianti BL, Dewhirst-Dvm MW, J Magn Reson Imaging 2008 27 1388 1398 10.1002/jmri.21344 18504759 (Pubitemid 351770694)
34. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. Koh DM, Scurr E, Collins D, Kanber B, Norman A, Leach MO, Husband JE, AJR Am J Roentgenol 2007 188 1001 1008 10.2214/AJR.06.0601 17377036 (Pubitemid 46496932)
35. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. Kamel IR, Bluemke DA, Eng J, Liapi E, Messersmith W, Reyes DK, Geschwind JF, J Vasc Interv Radiol 2006 17 505 512 10.1097/01.RVI.0000200052.02183.92 16567675 (Pubitemid 44318722)
36. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Harrison L, Blackwell K, Oncologist 2004 9 Suppl 5 31 40 15591420 (Pubitemid 39658343)
37. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. Jain RK, J Clin Oncol 2013 31 2205 2218 10.1200/JCO.2012.46.3653 23669226
38. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. Hamstra DA, Rehemtulla A, Ross BD, J Clin Oncol 2007 25 4104 4109 10.1200/JCO.2007.11.9610 17827460 (Pubitemid 47495868)
39. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. Dvorak HF, J Clin Oncol 2002 20 4368 4380 10.1200/JCO.2002.10.088 12409337 (Pubitemid 35266299)
40. Molecular mechanisms and clinical applications of angiogenesis. Carmeliet P, Jain RK, Nature 2011 473 298 307 10.1038/nature10144 21593862
41. AZD2171, A pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK, Cancer Cell 2007 11 83 95 10.1016/j.ccr.2006.11.021 17222792 (Pubitemid 46075199)
42. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI, J Clin Oncol 2006 24 16 24 10.1200/JCO.2005.02.2574 16330672 (Pubitemid 46630489)
43. Recombinant human tumor necrosis factor: an efficient agent for cancer treatment. Lejeune FJ, Ruegg C, Bull Cancer 2006 93 90 E100 16935777